PL4081523T3 - Podstawione bicykliczne pochodne piperydyny przydatne jako aktywatory komórek t - Google Patents
Podstawione bicykliczne pochodne piperydyny przydatne jako aktywatory komórek tInfo
- Publication number
- PL4081523T3 PL4081523T3 PL20842859.9T PL20842859T PL4081523T3 PL 4081523 T3 PL4081523 T3 PL 4081523T3 PL 20842859 T PL20842859 T PL 20842859T PL 4081523 T3 PL4081523 T3 PL 4081523T3
- Authority
- PL
- Poland
- Prior art keywords
- derivatives useful
- piperidine derivatives
- substituted bicyclic
- cell activators
- bicyclic piperidine
- Prior art date
Links
- 229940126530 T cell activator Drugs 0.000 title 1
- -1 bicyclic piperidine derivatives Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911053552 | 2019-12-23 | ||
| PCT/US2020/066507 WO2021133750A1 (en) | 2019-12-23 | 2020-12-22 | Substituted bicyclic piperidine derivatives useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4081523T3 true PL4081523T3 (pl) | 2025-03-10 |
Family
ID=74191945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20842859.9T PL4081523T3 (pl) | 2019-12-23 | 2020-12-22 | Podstawione bicykliczne pochodne piperydyny przydatne jako aktywatory komórek t |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11964973B2 (https=) |
| EP (1) | EP4081523B1 (https=) |
| JP (1) | JP7653440B2 (https=) |
| KR (1) | KR20220119455A (https=) |
| CN (1) | CN114901660B (https=) |
| AR (1) | AR120823A1 (https=) |
| AU (1) | AU2020412615A1 (https=) |
| BR (1) | BR112022012195A2 (https=) |
| CA (1) | CA3163013A1 (https=) |
| CL (1) | CL2022001710A1 (https=) |
| CO (1) | CO2022008675A2 (https=) |
| DK (1) | DK4081523T3 (https=) |
| ES (1) | ES3008848T3 (https=) |
| FI (1) | FI4081523T3 (https=) |
| HR (1) | HRP20250149T1 (https=) |
| HU (1) | HUE070934T2 (https=) |
| IL (1) | IL294272A (https=) |
| LT (1) | LT4081523T (https=) |
| MX (1) | MX2022007842A (https=) |
| PE (1) | PE20221487A1 (https=) |
| PL (1) | PL4081523T3 (https=) |
| PT (1) | PT4081523T (https=) |
| RS (1) | RS66482B1 (https=) |
| SI (1) | SI4081523T1 (https=) |
| SM (1) | SMT202500102T1 (https=) |
| TW (1) | TWI843922B (https=) |
| WO (1) | WO2021133750A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2023122778A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
| WO2023150186A1 (en) * | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| US20250215014A1 (en) * | 2022-03-31 | 2025-07-03 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| WO2024137865A1 (en) * | 2022-12-22 | 2024-06-27 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| EP4658650A1 (en) * | 2023-02-02 | 2025-12-10 | Beone Medicines I GmbH | Heterocyclic compounds |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2025030002A2 (en) * | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| BR0312204A (pt) | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
| WO2004087880A2 (en) | 2003-03-26 | 2004-10-14 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| EP1660087A2 (en) | 2003-07-22 | 2006-05-31 | Janssen Pharmaceutica N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| CN1839133A (zh) | 2003-08-22 | 2006-09-27 | 阿文尼尔药品公司 | 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用 |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP5422204B2 (ja) * | 2006-03-30 | 2014-02-19 | 国立大学法人 千葉大学 | ＤＧＫα阻害剤を含有する抗癌剤 |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| AU2007301958A1 (en) | 2006-09-29 | 2008-04-03 | Tibotec Pharmaceuticals Ltd. | Quinolinone derivatives |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| WO2012142498A2 (en) * | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR089939A1 (es) | 2012-02-09 | 2014-10-01 | Glenmark Pharmaceuticals Sa | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| PT3889145T (pt) | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| US10946020B2 (en) | 2016-04-06 | 2021-03-16 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US12187687B2 (en) | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| AU2018340475B2 (en) | 2017-09-28 | 2023-01-19 | Transthera Sciences (Nanjing), Inc. | PDE9 inhibitor and use thereof |
| KR102767739B1 (ko) | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| CN112585139B (zh) | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
| CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| US20230062100A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| US20230064809A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| CR20220236A (es) | 2019-11-28 | 2022-10-03 | Bayer Pharma AG | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune |
-
2020
- 2020-12-18 AR ARP200103557A patent/AR120823A1/es not_active Application Discontinuation
- 2020-12-22 DK DK20842859.9T patent/DK4081523T3/da active
- 2020-12-22 HR HRP20250149TT patent/HRP20250149T1/hr unknown
- 2020-12-22 PE PE2022001172A patent/PE20221487A1/es unknown
- 2020-12-22 KR KR1020227025285A patent/KR20220119455A/ko active Pending
- 2020-12-22 CN CN202080089196.XA patent/CN114901660B/zh active Active
- 2020-12-22 EP EP20842859.9A patent/EP4081523B1/en active Active
- 2020-12-22 US US17/130,022 patent/US11964973B2/en active Active
- 2020-12-22 LT LTEPPCT/US2020/066507T patent/LT4081523T/lt unknown
- 2020-12-22 SM SM20250102T patent/SMT202500102T1/it unknown
- 2020-12-22 SI SI202030567T patent/SI4081523T1/sl unknown
- 2020-12-22 FI FIEP20842859.9T patent/FI4081523T3/fi active
- 2020-12-22 JP JP2022538810A patent/JP7653440B2/ja active Active
- 2020-12-22 PT PT208428599T patent/PT4081523T/pt unknown
- 2020-12-22 IL IL294272A patent/IL294272A/en unknown
- 2020-12-22 HU HUE20842859A patent/HUE070934T2/hu unknown
- 2020-12-22 TW TW109145532A patent/TWI843922B/zh not_active IP Right Cessation
- 2020-12-22 ES ES20842859T patent/ES3008848T3/es active Active
- 2020-12-22 RS RS20250119A patent/RS66482B1/sr unknown
- 2020-12-22 CA CA3163013A patent/CA3163013A1/en active Pending
- 2020-12-22 PL PL20842859.9T patent/PL4081523T3/pl unknown
- 2020-12-22 WO PCT/US2020/066507 patent/WO2021133750A1/en not_active Ceased
- 2020-12-22 BR BR112022012195A patent/BR112022012195A2/pt unknown
- 2020-12-22 MX MX2022007842A patent/MX2022007842A/es unknown
- 2020-12-22 AU AU2020412615A patent/AU2020412615A1/en active Pending
-
2022
- 2022-06-20 CL CL2022001710A patent/CL2022001710A1/es unknown
- 2022-06-22 CO CONC2022/0008675A patent/CO2022008675A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020412615A1 (en) | 2022-08-18 |
| AR120823A1 (es) | 2022-03-23 |
| CN114901660B (zh) | 2024-10-15 |
| EP4081523A1 (en) | 2022-11-02 |
| FI4081523T3 (fi) | 2025-03-06 |
| BR112022012195A2 (pt) | 2022-09-06 |
| US20210188845A1 (en) | 2021-06-24 |
| CA3163013A1 (en) | 2021-07-01 |
| EP4081523B1 (en) | 2024-12-25 |
| TW202136254A (zh) | 2021-10-01 |
| JP2023508052A (ja) | 2023-02-28 |
| LT4081523T (lt) | 2025-05-12 |
| TWI843922B (zh) | 2024-06-01 |
| SI4081523T1 (sl) | 2025-04-30 |
| CN114901660A (zh) | 2022-08-12 |
| HUE070934T2 (hu) | 2025-07-28 |
| CL2022001710A1 (es) | 2023-01-13 |
| KR20220119455A (ko) | 2022-08-29 |
| WO2021133750A1 (en) | 2021-07-01 |
| SMT202500102T1 (it) | 2025-05-12 |
| IL294272A (en) | 2022-08-01 |
| CO2022008675A2 (es) | 2022-07-19 |
| PE20221487A1 (es) | 2022-09-26 |
| MX2022007842A (es) | 2022-07-19 |
| JP7653440B2 (ja) | 2025-03-28 |
| HRP20250149T1 (hr) | 2025-04-11 |
| DK4081523T3 (da) | 2025-03-10 |
| RS66482B1 (sr) | 2025-03-31 |
| US11964973B2 (en) | 2024-04-23 |
| ES3008848T3 (en) | 2025-03-25 |
| PT4081523T (pt) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4081523T3 (pl) | Podstawione bicykliczne pochodne piperydyny przydatne jako aktywatory komórek t | |
| ZA202100555B (en) | Substituted naphthyridinone compounds useful as t cell activators | |
| SMT202500489T1 (it) | Composti piridopirimidinonilici sostituiti utili come attivatori delle cellule t | |
| IL279730A (en) | Naphthyridinone compounds useful as T-cell activators | |
| EP3949998A4 (en) | CELL ACTIVATOR | |
| IL284767A (en) | Heterocyclic compounds as adenosine antagonists | |
| SG11202009543VA (en) | Piperidine compounds as covalent menin inhibitors | |
| IL293103B2 (en) | History of pyridopyrimidinones as AHR antagonists | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| EP3135674A4 (en) | Novel bicyclic or tricyclic heterocyclic compound | |
| IL284762A (en) | Heterocyclic compounds as adenosine antagonists | |
| EP3115362A4 (en) | Piperidine derivatives as orexin receptor antagonist | |
| GB201915191D0 (en) | Novel heterocyclic compounds | |
| HK40083244A (en) | Substituted bicyclic piperidine derivatives useful as t cell activators | |
| ZA202105729B (en) | Pentacyclic heterocyclic compound | |
| HK40073323A (en) | Substituted pyridopyrimidinonyl compounds useful as t cell activators | |
| HK40049509A (en) | Substituted naphthyridinone compounds useful as t cell activators | |
| HK40064784A (en) | Heterocyclic compounds as adenosine antagonists | |
| HK40070024A (en) | Bicyclic heterocyclic compounds as inhibitors ofbcdin3d activity | |
| HK40029095A (en) | Heterocyclic compounds as adenosine antagonists | |
| HK40079682A (en) | Novel heterocyclic compounds | |
| HK40054941A (en) | Pyridin-2-one compounds useful as smarca2 antagonists | |
| HK40036629A (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |